Jodi Lyn Black, CMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 184 E Paradise Ct, Saratoga Springs, UT 84045 Phone: 801-678-3971 |
Nicholas Baum, CMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 468 W Meadow Crest Way, Saratoga Springs, UT 84045 Phone: 385-207-8910 |
Mrs. Attica Yvette Schmidt, CMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4168 S Sunrise Dr, Saratoga Springs, UT 84045 Phone: 801-419-5525 |
Kyler Jay Griffith, MA Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1305 N Commerce Dr Ste 100, Saratoga Springs, UT 84045 Phone: 801-341-8274 |
Brynlee Ann Shults Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 104 W Medical Dr, Saratoga Springs, UT 84045 Phone: 180-195-5360 |
Deann Ellsworth Kettenring, ACMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 104 W Medical Dr Ste 1, Saratoga Springs, UT 84045 Phone: 801-955-3600 Fax: 801-955-3600 |
Deborah H Meese, APC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 24 W Sergeant Court Dr, Suite 202, Saratoga Springs, UT 84045 Phone: 801-558-5170 |
Jacob Grant Brown, CMHC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 2997 S Red Pine Dr, Saratoga Springs, UT 84045 Phone: 801-477-6257 |
News Archive
The Obama administration's final rule rescinding important elements of a federal regulation protecting the conscience rights of health care providers is a disappointment, but there are also reasons for hope, said Deirdre McQuade of the Pro-Life Secretariat of the United States Conference of Catholic Bishops (USCCB).
Manchester Metropolitan University is working with a cutting edge technology firm to find a treatment for the hospital superbug MRSA which kills 5,000 patients each year.
"Rethinking the Approach to Expanded Access Programs," Forum for Collaborative HIV Research: The report says that reform of expanded access programs that allow HIV-positive people to take new drugs before final federal approval is needed.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
› Verified 7 days ago